Manage your formulary budget
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||High affinity TGF.beta. nucleic acid ligands|
|Abstract:||Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF.beta.. Included in the invention are specific RNA and ssDNA ligands to TGF.beta.1 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF.beta.1 with its receptor.|
|Inventor(s):||Toothman; Penelope J. (Boulder, CO), Ringquist; Steven (Lyons, CO), Gold; Larry (Boulder, CO)|
|Assignee:||NeXstar Pharmaceuticals, Inc. (Boulder, CO)|
|Filing Date:||Jun 02, 1995|
|Claims:||1. A method of identifying nucleic acid ligands to transforming growth factor beta (TGF.beta.) comprising: |
a) preparing a candidate mixture of nucleic acids;
b) contacting the candidate mixture of nucleic acids with TGF.beta., wherein nucleic acids having an increased affinity to TGF.beta. relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and
d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acid sequences with relatively higher affinity and specificity for binding to TGF.beta., whereby nucleic acid ligands of TGF.beta. may be identified.
2. The method of claim 1 further comprising:
e) repeating steps b), c), and d).
3. The method of claim 1 wherein said candidate mixture of nucleic acids is comprised of single stranded nucleic acids.
4. The method of claim 3 wherein said single stranded nucleic acids are ribonucleic acids.
5. The method of claim 4 wherein said nucleic acids comprise 2'-amino (2'-NH.sub.2) modified ribonucleic acids.
6. The method of claim 4 wherein said nucleic acids comprise 2'-F modified ribonucleic acids.
7. The method of claim 4 wherein said nucleic acids comprise 2'-NH.sub.2 -UTP, 2'-F-CTP modified ribonucleic acids.
8. The method of claim 4 wherein said nucleic acids comprise 2'-F-UTP, 2'-NH.sub.2 -CTP modified ribonucleic acids.
9. The method of claim 3 wherein said single stranded nucleic acids are deoxyribonucleic acids.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.